Latest posts tagged with #CARTcells on Bluesky
"These observations underscore that eligibility for cellular immunotherapy should be guided by biological rather than chronological fitness—a principle of particular relevance for autoimmune diseases, which frequently affect older populations."
#Immunotherapy #Autoimmunity #CARTcells
Published today in Science Immunology: @sriv4000.bsky.social and team find a new way to give #CARTcells their own portable pit crew, allowing them to rejuvenate on the go and transforms them into a type of T cell that can support long-term immune responses against tumors. https://bit.ly/3NiSged
CXCR4hi #CARTcells boost #TumorTracking, #BoneMarrow homing, and persistence, enhancing #Antitumor activity; early trial data in B cell malignancies show multiple complete responses, supporting #CXCR4 modification.
#OpenAccess in #STTT: doi.org/10.1038/s413...
Ideal for scientists, transfusion professionals, MDs, and MSc/PhD students.
www.isbtweb.org/events/isbt-...
#CARTcells #CellTherapy #TransfusionMedicine
The key insight here is sensitivity. Solid tumors are heterogeneous, and #HITcells appear able to detect what #CARTcells miss. If finding the last #cancer cell is the problem, this work points to a potential solution.
www.linkedin.com/posts/drmelv...
Optimizing CAR-T Cell Therapy to Tackle Solid Tumors.
Researchers at LMU Klinikum München, in close collaboration with University of Tübingen, have taken an important step forward.
Read:
medicalxpress.com/news/2026-02...
#Immunotherapy #CARTcells #Oncology #CellTherapy #CancerResearch
Great presentation by my colleague Heather Landau on transformative results of BCMA #CARTcells for #amyloidosis #tandem26 @mskcancercenter.bsky.social @mskdeptofmed.bsky.social
My @mskcancercenter.bsky.social colleague Dr Roisin E. O'Cearbhaill discussing role of cell therapy at #tandem26 Joint session @astct.bsky.social @sitcancer.bsky.social #tcellrx #cartcells
FDA reflections on #CARTCells therapies and autoimmunity: the key challenge is finding the match between the right product and the right indication.
www.fiercebiotech.com/biotech/fda-...
Scientists show that engineering #CARTcells to overexpress #CXCR4 restores #CXCL12-guided migration, enhances #tumortracking and #BoneMarrow homing, promotes memory persistence, and improves #antitumor efficacy in #BcellLymphoma and #myeloma.
#STTT: doi.org/10.1038/s413...
🚀New paper alert and a great way to start the year for Philip and #TeamJJ!🚀 Our paper on enhancing T cell anti-tumor potency through CAR-adapted PIK3CD base editing is now out in Nature Cancer. For more details visit: www.nature.com/articles/s43...
#TeamJJ #NatureCancer #iFIT #CARTcells
Allogeneic #CARTCells in phase Ib/II clinical trials in China for the treatment of relapsed/refractory multiple myeloma (R/R MM) and primary plasma cell leukemia (pPCL). Phase I study showed interesting results.
buff.ly/SKuRXC9
Excited to share our paper that has been published in the @journalofnucmed.bsky.social
jnm.snmjournals.org/content/earl...
Our findings demonstrate the feasibility of PET-based CAR-T cell tracking in a solid tumor model through selective DOTA-hapten and Thor platform. #cartcells #immunotherapy
🚨 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗶𝗻 𝗖𝗔𝗥 𝗧-𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆!
Roswell Park researchers have developed IL-36 gamma “armored” CAR T cells that reprogram neutrophils to attack solid tumors.
🔗Read the full press release here: roswellpark.org/newsroom/202...
#CARTCells #RoswellPark
Kyverna to take autoimmune CAR-T to FDA after success in stiff person syndrome trial.
#CARTCells #Autoimmune disease
Researchers at @roswellpark.bsky.social Comprehensive #Cancer Center report in Cancer Cell that IL-36γ–armored #CARTcells can eradicate solid #tumors in preclinical models by reprogramming neutrophils and amplifying innate and adaptive anti #tumor #immunity.
www.linkedin.com/posts/drmelv...
Allogeneic anti-CD7 #CARTCells for relapsing T-ALL eradication prior to hematopoietic allograft!
Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia | New England Journal of Medicine buff.ly/7jYX07o
Very impressive preliminary results of in vivo BCMA #CARTcells. High expansion of CART, excellent responses with low toxicity without lymphodepletion #ash25 #mmsm 1/2
Proud to share this elegant work by the very talented Dr. Edward Song on the engineered overexpression of CXCR3 in #CARTcells to drive better trafficking to pediatric brain & spinal tumors (beautiful art by www.katierisvicari.com) #VitanzaLab @seattlechildrens.org
www.nature.com/articles/s41...
⚡Our November issue is out! Featuring trials of #CARTcells for #LUPUS, an #ADC for #lungcancer, cardiac #genetherapy, an #ebola #vaccine, discovery of microbial elements in #braintumors, #liquidbiopsies, #newbornscreening, News, Reviews, & more.
https://www.nature.com/nm/volumes/31/issues/11
A #ScienceSignaling study examines the activities of ligand-based #CARTcells and shows they induce proliferative signaling events within target cells, a finding that has implications for the design and application of future CAR T cells in the clinic. https://scim.ag/47CxSMB
New in Nature Reviews Chemistry: Jason Lohmueller and colleagues review small-molecule control systems for #CARTCells — addressing toxicity & resistance challenges in #cancer #immunotherapy
Read the article: www.nature.com/articles/s41...
Jennifer Doudna startup launches with $82M to apply new #CRISPR delivery technology to in vivo #CARTCells.
buff.ly/mewzZFL
#iPSC-derived, off-the-shelf anti-CD19 #CARTcells deliver improved clinical outcomes in lupus.
buff.ly/h2uH87G
As #ACRConvergence unfolds, one session really stood out “Driving CAR-T into the Future.”
With discussion of next-gen #Bcell targets (CD19, CD20, BCMA, autoreactive subsets), the field is moving from broad depletion to tailored immune precision.
#Lupus #AutoimmuneDisease #CARTcells
Epigenetics Update - Integrated epigenetic and genetic programming of primary human T cells go.nature.com/47AyUZd
#Epigenetic #Chromatin #TCells #CRISPR #CARTCells
---
Discover the breakthrough at epigenometech.com
🚀CAR-T cell therapy is showing promising results in #Brazil for lymphoma and leukemia patients, with survival rates of 73% and 79%. This advanced treatment offers new hope where other options have failed.
🔓https://doi.org/10.46765/2675-374X.2025v6n1p271
#CARTCells #CellTherapy #CancerTreatment
Sjoukje van der Stegen, from the Chan Zuckerberg Biohub New York share her works on iPS-derived #CARTCells.
#ITD2025
